MedPath

Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)

Not Applicable
Completed
Conditions
Schizophrenia
Interventions
Drug: clozapine+haloperidol
Drug: clozapine,electroconvulsive therapy
Registration Number
NCT00753051
Lead Sponsor
Khon Kaen University
Brief Summary

Clozapine treatment resistant schizophrenia is still prevalent.The effectiveness of augmenting clozapine : one augmenting with haloperidol and the other with electroconvulsive therapy should be determined.This study is a randomized control trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria
  1. schizophrenic patients diagnosed with schedules for clinical assessment in neuropsychiatry ( SCAN )in accordance with DSM-IV-TR or ICD-10
  2. Resistant to at least 6 weeks of clozapine treatment in therapeutic dosage
  3. Voluntary to participate the research protocol expressed by signing informed consent form
Exclusion Criteria
  1. Patient does not volunteer himself or herself
  2. Patient is having epilepsy, DM, cardiac disease, autistic disorder and illiterate
  3. Patient is deaf, blind , dumb to obstruct good communication

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1.clozapine+haloperidolclozapine as the main agent and it will be adjuncted by haloperidol
2.clozapine,electroconvulsive therapyclozapine as the main agent and it will be adjuncted by electroconvulsive therapy
Primary Outcome Measures
NameTimeMethod
PANSS , HAM-D , CGI , AIMS Scoresevery 4 weeks for 24 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Psychiatry.Faculty of Medicine.KhonKaen University.

🇹🇭

Muang, KhonKaen, Thailand

© Copyright 2025. All Rights Reserved by MedPath